Alto Neuroscience shelved its schizophrenia-related cognitive impairment program after a Phase 2 failure of its PDE4 inhibitor, the company said. The decision pauses further development and indicates Alto will shift resources away from the indication-specific strategy while reassessing pipeline priorities. Phase 2 misses in CNS cognitive endpoints often pressure biotech cash burn and can reset valuation expectations in early clinical franchises, particularly when there are no immediate alternative clinical reads. For investors and peers, the key takeaway is rapid portfolio reallocation after efficacy disappointments—continuing a market that rewards stronger differentiation in validated cognitive measures and biomarker-backed programs.